OKUR (OnKure Therapeutics) Moat Score: 3/10 (As of Jul. 06, 2026)


OKUR OnKure Therapeutics Inc OKUR
14 GF Score
Price $4.60
! 2 Warning Signs
View Full Analysis

What is OnKure Therapeutics Moat Score?

OnKure Therapeutics OKUR +2.46% 14 Moat Score is 3 as of Jul. 06, 2026. GuruFocus rates OKUR with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, OnKure Therapeutics ranks better than 75.48% on this metric.

OnKure Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

OnKure Therapeutics has No Moat: OnKure Therapeutics Inc is in a competitive biotech industry with limited market share and no significant intellectual property or regulatory advantages. The company lacks strong brand loyalty or cost advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes OnKure Therapeutics might have No Moat - Very weak/transient advantages.

OnKure Therapeutics  (NAS:OKUR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

OnKure Therapeutics Moat Score Related Terms

OKUR vs ANTX, PLX, KRRO: Moat Score Comparison

For the Biotechnology subindustry, OnKure Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OnKure Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OnKure Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where OnKure Therapeutics's Moat Score falls into.


OKUR
14GF Score
OnKure Therapeutics Inc OKUR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
OnKure Therapeutics (OKUR) has a Moat Score of 3 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, OnKure Therapeutics ranks #342 out of 1395 companies in the Biotechnology industry, placing it in the top 24.5%.
Is OnKure Therapeutics' Moat Score too high?
OnKure Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. OnKure Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, OnKure Therapeutics ranks #342 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OnKure Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does OnKure Therapeutics' Moat Score compare to ANTX and PLX?
According to the Biotechnology industry distribution chart, OnKure Therapeutics ranks #342 out of 1395 companies for Moat Score. This places OnKure Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. OnKure Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OnKure Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OnKure Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OnKure Therapeutics stock overvalued right now?
OnKure Therapeutics (OKUR) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. OnKure Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For OnKure Therapeutics (OKUR), the current Moat Score is 3 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OnKure Therapeutics Business Description

Address 6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
14GF Score

Get the complete analysis for OKUR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price